<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="368463">
  <stage>Registered</stage>
  <submitdate>4/05/2015</submitdate>
  <approvaldate>15/05/2015</approvaldate>
  <actrnumber>ACTRN12615000485538</actrnumber>
  <trial_identification>
    <studytitle>Physiology of Acute Coronary Syndromes: Evaluating the impacts of inflammation and microvascular dysfunction on long-term cardiovascular outcomes in patients with coronary artery disease </studytitle>
    <scientifictitle>Physiology of Acute Coronary Syndromes (ACS): The effects of colchicine versus standard medical therapy on long-term cardiovascular outcomes in ACS patients
</scientifictitle>
    <utrn>U1111-1169-8018 </utrn>
    <trialacronym>FOACS</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Acute coronary syndromes</healthcondition>
    <healthcondition>Coronary artery disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Participants will be receiving oral colchicine 0.5mg daily for 8 weeks in addition to standard medical therapy. 

Compliance to colchicine therapy will be monitored by counting the number of drug tablet returned at the end of study period. </interventions>
    <comparator>Standard medical therapy as per current acute coronary syndrome management guidelines which includes dual antiplatelet therapy, statin, beta blocker and angiotensin converting enzyme (ACE) inhibitor.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Atherosclerotic plaque vulnerability as assessed on Optical Coherence Tomography (OCT)
</outcome>
      <timepoint>8 weeks after randomisation</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Reduction in inflammatory markers (such as CRP, soluble RAGE, IL6 and CD40 ligand) as assessed using biochemical tests on patient serum samples.</outcome>
      <timepoint>8 weeks after randomisation</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Microvascular function as assessed using index of microvascular resistance (IMR) derived from intracoronary pressure-wire during coronary angiography</outcome>
      <timepoint>8 weeks after randomisation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Periprocedural myocardial infarction as assessed using biochemical tests (troponin and CKMB) on patient serum samples. These cardiac enzymes will be measured at baseline when patients return for staged PCI, as well as 6 hours and 12 hours after the procedure. </outcome>
      <timepoint>8 weeks after randomisation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Major adverse cardiovascular events: cardiovascular death, fatal or non-fatal myocardial infarction, urgent revascularization, and non-cardioembolic ischaemic stroke.
The information will be gathered from interviews and/or patient medical records. </outcome>
      <timepoint>8 weeks after randomisation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients admitted with acute coronary syndromes
Multivessel disease on coronary angiography with plan for staged PCI</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Severe hepatic and renal impairment
Patients who are intolerant of colchicine
Pre-existing colchicine use for other medical conditions
Concurrent administration of immunosuppressant therapy
Known active malignancy
Pregnancy or lactating women</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>All ACS patients who are admitted to the hospital will be screened for eligibility. Randomisation to colchicine therapy will occur after coronary angiography/angioplasty. Allocation is done using sealed opaque envelopes and is concealed from the investigators. </concealment>
    <sequence>Computerised sequence generation
</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods>Continuous variables will be summarized by means, standard deviations, medians and ranges. Categorical variables will be summarized by frequencies and percentages.

In order to assess comparability of treatment groups, subject demographics and other baseline characteristics will be tabulated separately by treatment group.

This is a proof-of-concept study designed to test the feasibility and safety of such intervention in ACS populations. The study is not designed to test the superiority of one treatment over the other. We anticipate to recruit 50 patients over a period of 12 months. If proven feasible and safe, a larger randomised controlled trial can be conducted to assess the efficacy of colchicine therapy in ACS.</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>19/05/2015</anticipatedstartdate>
    <actualstartdate>18/08/2015</actualstartdate>
    <anticipatedenddate>30/04/2016</anticipatedenddate>
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>St Vincent's Hospital (Melbourne) Ltd - Fitzroy</hospital>
    <hospital>Frankston Hospital - Frankston</hospital>
    <postcode>3065 - Fitzroy</postcode>
    <postcode>3199 - Frankston</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>St. Vincent's Hospital Melbourne</primarysponsorname>
    <primarysponsoraddress>41 Victoria Parade, Fitzroy 3065, Victoria</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>St. Vincent's Hospital Melbourne</fundingname>
      <fundingaddress>41 Victoria Parade, Fitzroy 3065, Victoria</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Frankston Hospital</sponsorname>
      <sponsoraddress>2 Hastings Road, Frankston 3199, Victoria</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims (1) to define the atherosclerotic plaque characteristics, inflammation and microvascular physiology in patients with acute coronary syndromes; (2) to evaluate the impacts of colchicine on atherosclerotic plaques, inflammation and microvascular physiology in ACS; and (3) to correlate plaque morphology and coronary physiology with future cardiac events</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St. Vincent's Health (Melbourne)</ethicname>
      <ethicaddress>41 Victoria Parade, Fitzroy 3065</ethicaddress>
      <ethicapprovaldate>15/04/2015</ethicapprovaldate>
      <hrec>HREC-A 010/10</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>David Tong</name>
      <address>59 Victoria Parade, Fitzroy 3065, Victoria</address>
      <phone>+61 3 9288 4452</phone>
      <fax>+61 3 8845 7073</fax>
      <email>DavidCK.Tong@svhm.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>David Tong</name>
      <address>59 Victoria Parade, Fitzroy 3065, Victoria</address>
      <phone>+61 3 9288 4452</phone>
      <fax>+61 3 8845 7073</fax>
      <email>DavidCK.Tong@svhm.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>David Tong</name>
      <address>59 Victoria Parade, Fitzroy 3065, Victoria</address>
      <phone>+61 3 9288 4452</phone>
      <fax>+61 3 8845 7073</fax>
      <email>DavidCK.Tong@svhm.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>David Tong</name>
      <address>59 Victoria Parade, Fitzroy 3065, Victoria</address>
      <phone>+61 3 9288 4452</phone>
      <fax>+61 3 8845 7073</fax>
      <email>DavidCK.Tong@svhm.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>